Weight Loss Drug Users Are 50% Less Likely to Get Alzheimer's

Ozempic, Wegovy Tied to Lower Alzheimer’s Risk With Type 2 Diabetes

GLP-1 drugs like Ozempic may help promote brain health, a new study suggests.

In the study, people with obesity who took Ozempic were 71 percent less likely to develop Alzheimer’s.

Key Takeaways

In a recent study, people with type 2 diabetes who took Ozempic appeared to lower their Alzheimer’s risk more than those using insulin. 

Ozempic was also linked to a greater reduction in Alzheimer’s risk compared with metformin and several other older diabetes drugs.

Brain health benefits of Ozempic didn’t change based on obesity status or gender.

Semaglutide, the main ingredient in the injected GLP-1 drugs Ozempic and Wegovy, is associated with a lower risk of Alzheimer’s disease in people with type 2 diabetes, a new study suggests.